Literature DB >> 21707844

Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.

Bungo Furusato1, Geert J H L van Leenders, Jan Trapman, Takahiro Kimura, Shin Egawa, Hiroyuki Takahashi, Masakuni Furusato, Tapio Visakorpi, Hiroshi Hano.   

Abstract

Chromosomal rearrangements that result in high expression levels of the ETS-related gene (ERG) present in approximately 50% of prostate cancer (PCa) patients, making this one of the most common oncogenic alterations in PCa. However, ERG overexpression at the protein level has not been rigorously evaluated in Japanese PCa patients. In this study, we evaluated ERG expression using antibody-based detection in 230 prostate specimens in a Japanese PCa cohort. Overall, we identified 20.1% ERG-positive PCa cases. ERG was not detected in benign glands. The specificity of ERG staining for detecting PCa was almost 100%; all of the ERG-positive samples were also diagnosed as PCa. The expression level of the ERG protein correlated with clinicopathological variables, including grade (P= 0.038), stage (P= 0.005), and metastatic status (P= 0.014). No correlation was observed with age (P= 0.196) or with preoperative prostate-specific antigen level (P= 0.322). Although the frequency of ERG-positive cases in Japanese PCa patients (20.1%) was lower than that reported in a PCa cohort in Western countries (approximately 50%), our study demonstrates that the clinical utility of ERG detection at the protein level can serve as an ancillary tool for diagnosing PCa in the Japanese population.
© 2011 The Authors. Pathology International © 2011 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707844     DOI: 10.1111/j.1440-1827.2011.02675.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  15 in total

1.  The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.

Authors:  Lillian Huang; Isaiah G Schauer; Jing Zhang; Imelda Mercado-Uribe; Michael T Deavers; Jiaoti Huang; Jinsong Liu
Journal:  Int J Clin Exp Pathol       Date:  2011-09-15

2.  Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.

Authors:  Ramy A Abdelsalam; Ibrahim Khalifeh; Alan Box; Maria Kalantarian; Sunita Ghosh; Hatem Abou-Ouf; Tamara Lotfi; Mohammed Shahait; Nallasivam Palanisamy; Tarek A Bismar
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

3.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

4.  TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Authors:  Hui Jiang; Xueying Mao; Xiaoyi Huang; Jing Zhao; Lumei Wang; Jingjing Xu; Hongwei Zhang; Yongjie Lu; Yongwei Yu
Journal:  Tumour Biol       Date:  2016-06-20

Review 5.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

6.  Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics.

Authors:  Najla Aldaoud; Nour Abdo; Samir Al Bashir; Mohammad Alqudah; Noor Marji; Hiba Alzou'bi; Rami Alazab; Kiril Trpkov
Journal:  Virchows Arch       Date:  2017-05-26       Impact factor: 4.064

7.  ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

Authors:  Gregory M Kelly; Yink Heay Kong; Albert Dobi; Shiv Srivastava; Isabell A Sesterhenn; Rajadurai Pathmanathan; Hui Meng Tan; Shyh-Han Tan; Sok Ching Cheong
Journal:  Mol Clin Oncol       Date:  2014-09-18

Review 8.  Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.

Authors:  Yanhong Yao; Haitao Wang; BaoGuo Li; Yong Tang
Journal:  Tumour Biol       Date:  2013-10-20

9.  ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer.

Authors:  L I Lu; Hao Zhang; Jun Pang; Guo-Liang Hou; Min-Hua Lu; Xin Gao
Journal:  Oncol Lett       Date:  2016-02-25       Impact factor: 2.967

10.  ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients.

Authors:  Ja Hee Suh; Jeong-Whan Park; Cheol Lee; Kyung Chul Moon
Journal:  Korean J Pathol       Date:  2012-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.